COMPANY PROFILE

ZYUS

Developing and commercializing cannabinoid-based pharmaceutical therapies for pain management, aiming to establish non-opioid treatments as a new standard of care

Saskatoon, CanadaFounded 2018Biotech & Life Sciences

Valuation $30M Market cap · 2026

Revenue $297K Latest reported FY

About ZYUS

ZYUS Life Sciences is a Canadian-based life sciences company specializing in the global development and commercialization of cannabinoid-based pharmaceutical drug products and innovative exempt market therapeutics. The company focuses on advancing the science of well-being by elevating cannabinoid formulations as a standard of care and expanding the potential of protein-based formulations. ZYUS serves patients who seek alternative and effective treatments for pain and other conditions, operating primarily in the medical and pharmaceutical markets. The business model revolves around clinical research, intellectual property protection, and the production of high-quality, compliant cannabinoid products. Revenue is generated through the sale of these pharmaceutical products and therapeutics in the global medical market.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2018
Headquarters: Saskatoon, Canada
Listing: IPO 2023
Employees: 54
Open positions: None listed
Dealroom signal: 37.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Investment activity: 1 company, latest Jun 2023
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	Aug 2026	$1.4M	—	Undisclosed	↗
POST IPO DEBT✓Debt	Aug 2026	$202K	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$297K	0%	−$8.7M	-2945.7%	−$16M	-5365.7%	$2.1M
2025	$297K	-15.8%	−$8.7M	-2945.7%	−$16M	-5365.7%	$2.1M
2024	$353K	+37%	−$8.8M	-2507.9%	−$25M	-7028.1%	$1.5M
2023	$257K	+17.8%	−$12M	-4734.2%			$960K
2022	$219K	+44%	−$9.1M	-4174.8%
2021	$152K	—	−$14M	-8964.3%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ZYUS website traffic

Latest recorded traffic for ZYUS is 1.4K monthly website visits, down 30% over the last three months. ZYUS's team declined 1.8% over the past year.

Latest monthly visits1.4K 3-month web change-30% 1-year team growth-1.8%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SMSuperluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created	Boston, United States	Operational	60	$213M	$240M
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
JBJunhemeng BiopharmaceuticalA company developing recombinant protein drugs for metabolism, medical aesthetics and other large markets	China	Operational
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational
PIPinTherapeuticsA pharmaceutical startup focusing on advanced protein degradation therapeutics	Seongnam-si, South Korea	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
MTMedilink TherapeuticsBiotech company focusing on next-generation antibody-drug conjugate research and development	Suzhou Shi, China	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational